Related Experiment Video

Updated: Feb 15, 2026

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

15.4K

Thrombopoietin and its receptor expression in pediatric patients with chronic immune thrombocytopenia

Shanshan Li1, Jingbo Shao1, Min Xia2

  • 1a Department of Hematology and Oncology , Shanghai Children's Hospital, Shanghai Jiao Tong University , Shanghai , People's Republic of China.

Hematology (Amsterdam, Netherlands)
|January 10, 2018
PubMed

Insights

Thrombopoietin (TPO) and its receptor c-Mpl levels are decreased in children with chronic immune thrombocytopenia (cITP). This suggests TPO and c-Mpl play a role in the development of childhood cITP.

Area of Science:

  • Hematology
  • Immunology
  • Pediatrics

Background:

  • Chronic immune thrombocytopenia (cITP) is a prevalent condition in children.
  • The exact mechanisms driving childhood cITP remain incompletely understood.

Purpose of the Study:

  • To investigate the potential role of thrombopoietin (TPO) and its receptor, c-Mpl, in the pathogenesis of childhood cITP.
  • To compare TPO and c-Mpl levels in children with newly diagnosed ITP (nITP), persistent ITP, cITP, and healthy controls.

Main Methods:

  • Plasma TPO levels were quantified using ELISA.
  • c-Mpl expression was determined by flow cytometry.
  • TPO and c-Mpl mRNA expression were analyzed using quantitative real-time PCR.

Main Results:

  • Plasma TPO levels were significantly lower in the cITP group compared to the nITP group.
  • c-Mpl expression (MFI) was significantly reduced in children with cITP versus those with nITP.
  • TPO and c-Mpl mRNA expression levels were also found to be decreased in the cITP group.

Conclusions:

  • Reduced expression of TPO and c-Mpl in children with cITP suggests their involvement in the disease's development.
  • These findings highlight TPO and c-Mpl as potential targets for understanding and managing childhood cITP.
Abstract

Keywords:
Immune thrombocytopeniac-Mplchronicthrombopoietin

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.8K
T and B Cell Receptor Immune Repertoire Analysis using Next-generation Sequencing08:59

T and B Cell Receptor Immune Repertoire Analysis using Next-generation Sequencing

Published on: January 12, 2021

8.9K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
281
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
318
What is the Immune System?01:38

What is the Immune System?

Overview
133.3K
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.8K